[A case of interferon beta-induced pneumonia]

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Cerebral glioblastoma treatment often involves a combination of chemotherapy, radiation, and immunotherapy.
• Interferon beta is used in some oncological treatments, but its pulmonary side effects are infrequently reported.
• Nimustine hydrochloride (ACNU) and brain irradiation are standard glioblastoma therapies.

Observation:

• A 58-year-old male treated for glioblastoma developed fever, cough, and dyspnea one month after nimustine hydrochloride, interferon beta, and brain irradiation.
• Chest imaging revealed diffuse ground-glass opacities, and bronchoalveolar lavage showed lymphocytic and neutrophilic alveolitis with a decreased CD4/8 ratio.
• Symptoms and radiographic findings worsened progressively, indicating a severe pulmonary reaction.

Findings:

• The patient's condition rapidly improved after discontinuing interferon beta and initiating high-dose steroid therapy.
• Bronchoalveolar lavage results indicated an inflammatory pneumonitis consistent with a drug-induced reaction.
• The clinical presentation and resolution strongly suggest interferon beta as the causative agent for the pneumonia.

Implications:

• This case underscores the potential for rare but severe pulmonary toxicity from interferon beta, even at doses used adjunctively in oncology.
• Early recognition and cessation of interferon beta, coupled with prompt corticosteroid treatment, are crucial for managing interferon beta-induced pneumonia.
• Further investigation into the mechanisms and risk factors for interferon beta-associated lung injury is warranted to improve patient safety.